Potential medicinal value of N6-methyladenosine in autoimmune diseases and tumours
Autoimmune diseases (ADs) are closely related to malignant tumours. On the one hand, ADs can increase the incidence of tumours; on the other hand, malignant tumours can cause rheumatic disease-like manifestations. With the increasing depth of analysis into the mechanism of N -methyladenosine (m6A) m...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2023-02 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | British journal of pharmacology |
| container_volume | |
| creator | Geng, Qishun Cao, Xiaoxue Fan, Danping Wang, Qiong Wang, Xing Zhang, Mengxiao Zhao, Lu Jiao, Yi Deng, Tingting Liu, Honglin Zhou, Jing Lou, Yanni Liang, Jing Xiao, Cheng |
| description | Autoimmune diseases (ADs) are closely related to malignant tumours. On the one hand, ADs can increase the incidence of tumours; on the other hand, malignant tumours can cause rheumatic disease-like manifestations. With the increasing depth of analysis into the mechanism of N
-methyladenosine (m6A) modification, it has been found that changes in m6A-related modification enzymes are closely related to the occurrence and development of ADs and malignant tumours. In this review, we explore the pathogenesis of ADs and tumours based on m6A modification. According to systematic assessment of the similarities between ADs and tumours, m6A may represent a common target of both diseases. At present, most of the drugs targeting m6A are in the research and development stage, not in clinical trials. Therefore, advancing the development of drugs targeting m6A is of great significance for both the combined treatment of ADs and malignant tumours and improving the quality of life and prognosis of patients. |
| doi_str_mv | 10.1111/bph.16030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2763334872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763334872</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-19a1b9662a64df9e5774a1e59a0e431707b06b65a46c6613bd3f22bc9a40c8aa3</originalsourceid><addsrcrecordid>eNo9kE1LxDAQhoMo7rp68A9IjnromjRp0h5l8QsWFdFzmaZTNtI2tWmE_fdGd3UuM8M8vAwPIeecLXms62rYLLligh2QOZdaJZnI-SGZM8Z0wnmez8iJ9x-MxaPOjslMKJXKTIk5eX1xE_aThZZ2WFtj-zh9QRuQuoY-qaTDabNtocbeedsjtT2FMDnbdSFutfUIHj2FvqZT6FwY_Sk5aqD1eLbvC_J-d_u2ekjWz_ePq5t1YkTKpoQXwKsiPgJK1k2BmdYSOGYFMJSCa6YrpiqVgVRGKS6qWjRpWpkCJDM5gFiQy13uMLrPgH4qO-sNti306IIvU62EEDLXaUSvdqgZnfcjNuUw2g7GbclZ-aOwjArLX4WRvdjHhioq-Sf_nIlvMHVsNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2763334872</pqid></control><display><type>article</type><title>Potential medicinal value of N6-methyladenosine in autoimmune diseases and tumours</title><source>Wiley Free Archive</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Geng, Qishun ; Cao, Xiaoxue ; Fan, Danping ; Wang, Qiong ; Wang, Xing ; Zhang, Mengxiao ; Zhao, Lu ; Jiao, Yi ; Deng, Tingting ; Liu, Honglin ; Zhou, Jing ; Lou, Yanni ; Liang, Jing ; Xiao, Cheng</creator><creatorcontrib>Geng, Qishun ; Cao, Xiaoxue ; Fan, Danping ; Wang, Qiong ; Wang, Xing ; Zhang, Mengxiao ; Zhao, Lu ; Jiao, Yi ; Deng, Tingting ; Liu, Honglin ; Zhou, Jing ; Lou, Yanni ; Liang, Jing ; Xiao, Cheng</creatorcontrib><description>Autoimmune diseases (ADs) are closely related to malignant tumours. On the one hand, ADs can increase the incidence of tumours; on the other hand, malignant tumours can cause rheumatic disease-like manifestations. With the increasing depth of analysis into the mechanism of N
-methyladenosine (m6A) modification, it has been found that changes in m6A-related modification enzymes are closely related to the occurrence and development of ADs and malignant tumours. In this review, we explore the pathogenesis of ADs and tumours based on m6A modification. According to systematic assessment of the similarities between ADs and tumours, m6A may represent a common target of both diseases. At present, most of the drugs targeting m6A are in the research and development stage, not in clinical trials. Therefore, advancing the development of drugs targeting m6A is of great significance for both the combined treatment of ADs and malignant tumours and improving the quality of life and prognosis of patients.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.16030</identifier><identifier>PMID: 36624563</identifier><language>eng</language><publisher>England</publisher><ispartof>British journal of pharmacology, 2023-02</ispartof><rights>2023 British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-19a1b9662a64df9e5774a1e59a0e431707b06b65a46c6613bd3f22bc9a40c8aa3</citedby><cites>FETCH-LOGICAL-c320t-19a1b9662a64df9e5774a1e59a0e431707b06b65a46c6613bd3f22bc9a40c8aa3</cites><orcidid>0000-0002-2475-7783</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36624563$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geng, Qishun</creatorcontrib><creatorcontrib>Cao, Xiaoxue</creatorcontrib><creatorcontrib>Fan, Danping</creatorcontrib><creatorcontrib>Wang, Qiong</creatorcontrib><creatorcontrib>Wang, Xing</creatorcontrib><creatorcontrib>Zhang, Mengxiao</creatorcontrib><creatorcontrib>Zhao, Lu</creatorcontrib><creatorcontrib>Jiao, Yi</creatorcontrib><creatorcontrib>Deng, Tingting</creatorcontrib><creatorcontrib>Liu, Honglin</creatorcontrib><creatorcontrib>Zhou, Jing</creatorcontrib><creatorcontrib>Lou, Yanni</creatorcontrib><creatorcontrib>Liang, Jing</creatorcontrib><creatorcontrib>Xiao, Cheng</creatorcontrib><title>Potential medicinal value of N6-methyladenosine in autoimmune diseases and tumours</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Autoimmune diseases (ADs) are closely related to malignant tumours. On the one hand, ADs can increase the incidence of tumours; on the other hand, malignant tumours can cause rheumatic disease-like manifestations. With the increasing depth of analysis into the mechanism of N
-methyladenosine (m6A) modification, it has been found that changes in m6A-related modification enzymes are closely related to the occurrence and development of ADs and malignant tumours. In this review, we explore the pathogenesis of ADs and tumours based on m6A modification. According to systematic assessment of the similarities between ADs and tumours, m6A may represent a common target of both diseases. At present, most of the drugs targeting m6A are in the research and development stage, not in clinical trials. Therefore, advancing the development of drugs targeting m6A is of great significance for both the combined treatment of ADs and malignant tumours and improving the quality of life and prognosis of patients.</description><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kE1LxDAQhoMo7rp68A9IjnromjRp0h5l8QsWFdFzmaZTNtI2tWmE_fdGd3UuM8M8vAwPIeecLXms62rYLLligh2QOZdaJZnI-SGZM8Z0wnmez8iJ9x-MxaPOjslMKJXKTIk5eX1xE_aThZZ2WFtj-zh9QRuQuoY-qaTDabNtocbeedsjtT2FMDnbdSFutfUIHj2FvqZT6FwY_Sk5aqD1eLbvC_J-d_u2ekjWz_ePq5t1YkTKpoQXwKsiPgJK1k2BmdYSOGYFMJSCa6YrpiqVgVRGKS6qWjRpWpkCJDM5gFiQy13uMLrPgH4qO-sNti306IIvU62EEDLXaUSvdqgZnfcjNuUw2g7GbclZ-aOwjArLX4WRvdjHhioq-Sf_nIlvMHVsNg</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Geng, Qishun</creator><creator>Cao, Xiaoxue</creator><creator>Fan, Danping</creator><creator>Wang, Qiong</creator><creator>Wang, Xing</creator><creator>Zhang, Mengxiao</creator><creator>Zhao, Lu</creator><creator>Jiao, Yi</creator><creator>Deng, Tingting</creator><creator>Liu, Honglin</creator><creator>Zhou, Jing</creator><creator>Lou, Yanni</creator><creator>Liang, Jing</creator><creator>Xiao, Cheng</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2475-7783</orcidid></search><sort><creationdate>20230201</creationdate><title>Potential medicinal value of N6-methyladenosine in autoimmune diseases and tumours</title><author>Geng, Qishun ; Cao, Xiaoxue ; Fan, Danping ; Wang, Qiong ; Wang, Xing ; Zhang, Mengxiao ; Zhao, Lu ; Jiao, Yi ; Deng, Tingting ; Liu, Honglin ; Zhou, Jing ; Lou, Yanni ; Liang, Jing ; Xiao, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-19a1b9662a64df9e5774a1e59a0e431707b06b65a46c6613bd3f22bc9a40c8aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geng, Qishun</creatorcontrib><creatorcontrib>Cao, Xiaoxue</creatorcontrib><creatorcontrib>Fan, Danping</creatorcontrib><creatorcontrib>Wang, Qiong</creatorcontrib><creatorcontrib>Wang, Xing</creatorcontrib><creatorcontrib>Zhang, Mengxiao</creatorcontrib><creatorcontrib>Zhao, Lu</creatorcontrib><creatorcontrib>Jiao, Yi</creatorcontrib><creatorcontrib>Deng, Tingting</creatorcontrib><creatorcontrib>Liu, Honglin</creatorcontrib><creatorcontrib>Zhou, Jing</creatorcontrib><creatorcontrib>Lou, Yanni</creatorcontrib><creatorcontrib>Liang, Jing</creatorcontrib><creatorcontrib>Xiao, Cheng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geng, Qishun</au><au>Cao, Xiaoxue</au><au>Fan, Danping</au><au>Wang, Qiong</au><au>Wang, Xing</au><au>Zhang, Mengxiao</au><au>Zhao, Lu</au><au>Jiao, Yi</au><au>Deng, Tingting</au><au>Liu, Honglin</au><au>Zhou, Jing</au><au>Lou, Yanni</au><au>Liang, Jing</au><au>Xiao, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential medicinal value of N6-methyladenosine in autoimmune diseases and tumours</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2023-02-01</date><risdate>2023</risdate><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Autoimmune diseases (ADs) are closely related to malignant tumours. On the one hand, ADs can increase the incidence of tumours; on the other hand, malignant tumours can cause rheumatic disease-like manifestations. With the increasing depth of analysis into the mechanism of N
-methyladenosine (m6A) modification, it has been found that changes in m6A-related modification enzymes are closely related to the occurrence and development of ADs and malignant tumours. In this review, we explore the pathogenesis of ADs and tumours based on m6A modification. According to systematic assessment of the similarities between ADs and tumours, m6A may represent a common target of both diseases. At present, most of the drugs targeting m6A are in the research and development stage, not in clinical trials. Therefore, advancing the development of drugs targeting m6A is of great significance for both the combined treatment of ADs and malignant tumours and improving the quality of life and prognosis of patients.</abstract><cop>England</cop><pmid>36624563</pmid><doi>10.1111/bph.16030</doi><orcidid>https://orcid.org/0000-0002-2475-7783</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2023-02 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2763334872 |
| source | Wiley Free Archive; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection; EZB Electronic Journals Library |
| title | Potential medicinal value of N6-methyladenosine in autoimmune diseases and tumours |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T11%3A44%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20medicinal%20value%20of%20N6-methyladenosine%20in%20autoimmune%20diseases%20and%20tumours&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Geng,%20Qishun&rft.date=2023-02-01&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.16030&rft_dat=%3Cproquest_cross%3E2763334872%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2763334872&rft_id=info:pmid/36624563&rfr_iscdi=true |